Recent Quotes (30 days)

You have no recent quotes
chg | %

CONMED Corporation  

(Public, NASDAQ:CNMD)   Watch this stock  
Find more results for CNMD
52.13
+0.21 (0.40%)
After Hours: 52.13 0.00 (0.00%)
Nov 17, 4:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 50.98 - 52.63
52 week 39.74 - 54.47
Open 51.59
Vol / Avg. 122,419.00/87,384.00
Mkt cap 1.46B
P/E 94.81
Div/yield 0.20/1.53
EPS 0.55
Shares 27.93M
Beta 0.66
Inst. own 101%
Jan 30, 2018
Q4 2017 Conmed Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 2, 2017
Q3 2017 Conmed Corp Earnings Call - Webcast
Nov 2, 2017
Q3 2017 Conmed Corp Earnings Release
Sep 12, 2017
Conmed Corp at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 3.79% 1.92%
Operating margin 7.09% 4.93%
EBITD margin - 16.85%
Return on average assets 2.14% 1.21%
Return on average equity 4.93% 2.52%
Employees 3,300 -
CDP Score - -

Address

525 French Rd
UTICA, NY 13502-5945
United States - Map
+1-315-6243215 (Phone)
+1-315-7970321 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company's products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company's orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Officers and directors

Mark E. Tryniski Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Curt R. Hartman President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Luke A. Pomilio Chief Financial Officer, Executive Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Patrick J. Beyer President of CONMED International
Age: 51
Bio & Compensation  - Reuters
Daniel S. Jonas Executive Vice President - Legal Affairs, General Counsel
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Heather L. Cohen Executive Vice President - Human Resources, Secretary
Age: 44
Bio & Compensation  - Reuters
Wilfredo Ruiz-Caban Executive Vice President - Quality Assurance, Regulatory Affairs and Operations
Age: 52
Bio & Compensation  - Reuters
Peter K. Shagory Executive Vice President - Strategy and Corporate Development
Age: 48
Bio & Compensation  - Reuters
Nathan Folkert Vice President, General Manager - U.S. Orthopedics Business
Age: 42
Bio & Compensation  - Reuters
John E. Kennedy Vice President and General Manager - U.S. Endoscopic Technologies
Age: 59
Bio & Compensation  - Reuters